186 related articles for article (PubMed ID: 26980090)
1. Yeast-based assays for screening 11β-HSD1 inhibitors.
Vanella R; Callari R; Weston A; Heider H; Schwab MS; Kübler E
Microb Cell Fact; 2016 Mar; 15():52. PubMed ID: 26980090
[TBL] [Abstract][Full Text] [Related]
2. Type 1 11beta-hydroxysteroid dehydrogenase as universal drug target in metabolic diseases?
Oppermann U
Endocr Metab Immune Disord Drug Targets; 2006 Sep; 6(3):259-69. PubMed ID: 17017977
[TBL] [Abstract][Full Text] [Related]
3. Cell-based assay for screening 11beta-hydroxysteroid dehydrogenase inhibitors using liquid chromatography/tandem mass spectrometry detection.
Xu R; Sang BC; Navre M; Kassel DB
Rapid Commun Mass Spectrom; 2006; 20(11):1643-7. PubMed ID: 16636996
[TBL] [Abstract][Full Text] [Related]
4. 11beta-hydroxysteroid dehydrogenase type 1 and obesity.
Morton NM; Seckl JR
Front Horm Res; 2008; 36():146-164. PubMed ID: 18230901
[TBL] [Abstract][Full Text] [Related]
5. Addressing the role of 11β-hydroxysteroid dehydrogenase type 1 in the development of polycystic ovary syndrome and the putative therapeutic effects of its selective inhibition in a preclinical model.
Li X; Hu S; Zhu Q; Yao G; Yao J; Li J; Wang Y; Ding Y; Qi J; Xu R; Zhao H; Zhu Z; Du Y; Sun K; Sun Y
Metabolism; 2021 Jun; 119():154749. PubMed ID: 33722534
[TBL] [Abstract][Full Text] [Related]
6. Cell-based assay for screening 11beta-hydroxysteroid dehydrogenase 1 inhibitors.
Cho YS; Kim CH; Cheon HG
Anal Biochem; 2009 Sep; 392(2):110-6. PubMed ID: 19497289
[TBL] [Abstract][Full Text] [Related]
7. Identification of a novel 11β-HSD1 inhibitor from a high-throughput screen of natural product extracts.
Park SB; Park JS; Jung WH; Park A; Jo SR; Kim HY; Dal Rhee S; Ryu SY; Jeong HG; Park S; Lee H; Kim KY
Pharmacol Res; 2015 Dec; 102():245-53. PubMed ID: 26515507
[TBL] [Abstract][Full Text] [Related]
8. Extra-adrenal regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological target for energy partitioning.
Walker BR
Proc Nutr Soc; 2007 Feb; 66(1):1-8. PubMed ID: 17343766
[TBL] [Abstract][Full Text] [Related]
9. 11beta-Hydroxysteroid dehydrogenase expression and glucocorticoid synthesis are directed by a molecular switch during osteoblast differentiation.
Eijken M; Hewison M; Cooper MS; de Jong FH; Chiba H; Stewart PM; Uitterlinden AG; Pols HA; van Leeuwen JP
Mol Endocrinol; 2005 Mar; 19(3):621-31. PubMed ID: 15591536
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy.
Wang M
Handb Exp Pharmacol; 2011; (203):127-46. PubMed ID: 21484570
[TBL] [Abstract][Full Text] [Related]
11. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
Anagnostis P; Katsiki N; Adamidou F; Athyros VG; Karagiannis A; Kita M; Mikhailidis DP
Metabolism; 2013 Jan; 62(1):21-33. PubMed ID: 22652056
[TBL] [Abstract][Full Text] [Related]
12. In vivo evaluation of 11beta-hydroxysteroid dehydrogenase activity in the rabbit eye.
Anderson S; Carreiro S; Quenzer T; Gale D; Xiang C; Gukasyan H; Lafontaine J; Cheng H; Krauss A; Prasanna G
J Ocul Pharmacol Ther; 2009 Jun; 25(3):215-22. PubMed ID: 19456256
[TBL] [Abstract][Full Text] [Related]
13. Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.
Masuzaki H; Flier JS
Curr Drug Targets Immune Endocr Metabol Disord; 2003 Dec; 3(4):255-62. PubMed ID: 14683456
[TBL] [Abstract][Full Text] [Related]
14. Metyrapone is a competitive inhibitor of 11beta-hydroxysteroid dehydrogenase type 1 reductase.
Sampath-Kumar R; Yu M; Khalil MW; Yang K
J Steroid Biochem Mol Biol; 1997 Jun; 62(2-3):195-9. PubMed ID: 9393954
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 lowers intraocular pressure in patients with ocular hypertension.
Rauz S; Cheung CM; Wood PJ; Coca-Prados M; Walker EA; Murray PI; Stewart PM
QJM; 2003 Jul; 96(7):481-90. PubMed ID: 12881590
[TBL] [Abstract][Full Text] [Related]
16. Growth hormone, insulin-like growth factor-I and the cortisol-cortisone shuttle.
Stewart PM; Toogood AA; Tomlinson JW
Horm Res; 2001; 56 Suppl 1():1-6. PubMed ID: 11786677
[TBL] [Abstract][Full Text] [Related]
17. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development.
Ge R; Huang Y; Liang G; Li X
Curr Med Chem; 2010; 17(5):412-22. PubMed ID: 20015040
[TBL] [Abstract][Full Text] [Related]
18. Green tea and one of its constituents, Epigallocatechine-3-gallate, are potent inhibitors of human 11β-hydroxysteroid dehydrogenase type 1.
Hintzpeter J; Stapelfeld C; Loerz C; Martin HJ; Maser E
PLoS One; 2014; 9(1):e84468. PubMed ID: 24404164
[TBL] [Abstract][Full Text] [Related]
19. A rapid screening assay for inhibitors of 11beta-hydroxysteroid dehydrogenases (11beta-HSD): flavanone selectively inhibits 11beta-HSD1 reductase activity.
Schweizer RA; Atanasov AG; Frey BM; Odermatt A
Mol Cell Endocrinol; 2003 Dec; 212(1-2):41-9. PubMed ID: 14654249
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel 11β-HSD1 inhibitors by combined ligand- and structure-based virtual screening.
Lagos CF; Vecchiola A; Allende F; Fuentes CA; Tichauer JE; Valdivia C; Solari S; Campino C; Tapia-Castillo A; Baudrand R; Villarroel P; Cifuentes M; Owen GI; Carvajal CA; Fardella CE
Mol Cell Endocrinol; 2014 Mar; 384(1-2):71-82. PubMed ID: 24447464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
